CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 447 filers reported holding CRISPR THERAPEUTICS AG in Q2 2024. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $6,898,284 | -33.1% | 126,900 | -14.7% | 0.01% | -33.3% |
| Q1 2024 | $10,304,910 | +54.3% | 148,700 | +40.8% | 0.01% | +50.0% |
| Q4 2023 | $6,677,088 | +32.4% | 105,600 | -2.3% | 0.01% | +14.3% |
| Q3 2023 | $5,042,865 | -8.1% | 108,100 | +13.4% | 0.01% | -12.5% |
| Q2 2023 | $5,488,327 | +20.7% | 95,300 | -5.8% | 0.01% | +14.3% |
| Q1 2023 | $4,547,928 | +12.3% | 101,200 | -0.8% | 0.01% | +16.7% |
| Q4 2022 | $4,049,400 | -30.0% | 102,000 | +16.0% | 0.01% | -33.3% |
| Q3 2022 | $5,786,000 | +7.3% | 87,900 | -0.9% | 0.01% | +12.5% |
| Q2 2022 | $5,392,000 | -13.9% | 88,700 | -8.6% | 0.01% | 0.0% |
| Q1 2022 | $6,266,000 | -17.0% | 97,000 | +3.1% | 0.01% | -11.1% |
| Q4 2021 | $7,549,000 | -11.2% | 94,100 | +24.5% | 0.01% | -18.2% |
| Q3 2021 | $8,497,000 | – | 75,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |